Dr. Michael J. Grant II, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 311
Licensed in Connecticut since 2022, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CT license 72107 (first issued 2022; active) -
Hematology (Internal Medicine) Physician
CT license 72107 (first issued 2022; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Saint Mary's Hospital Waterbury, CT
- Waterbury Hospital Waterbury, CT
Medical groups
- Yale University (2,645 clinicians)
- Yale New Haven Hospital (44 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 311
- Services billed
- 10,105
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 267 | 93 |
| Established patient office or other outpatient visit, 30-39 minutes | 237 | 140 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 90 | 49 |
| Insertion of needle into vein for collection of blood sample | 86 | 36 |
| Established patient office or other outpatient visit, 20-29 minutes | 81 | 68 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 77 | 32 |
| Blood test, comprehensive group of blood chemicals | 76 | 33 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 62 | 56 |
| New patient office or other outpatient visit, 45-59 minutes | 34 | 34 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in New Haven, CT | 112 |
| Xtandi (enzalutamide) | 72 |
| Prochlorperazine Maleate Other prescribers in New Haven, CT | 68 |
| Eliquis (apixaban) Other prescribers in New Haven, CT | 65 |
| Abiraterone Acetate | 61 |
| Hydroxyurea Other prescribers in New Haven, CT | 47 |
| Oxycodone Hcl Other prescribers in New Haven, CT | 46 |
| Xarelto (rivaroxaban) Other prescribers in New Haven, CT | 44 |
| Dexamethasone Other prescribers in New Haven, CT | 41 |
| Ondansetron Odt (ondansetron) Other prescribers in New Haven, CT | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $44,580 in research payments for these studies, mostly to the institutions running them.
- A randomized phase 3 openlabel study to evaluate SGNB6A compared with docetaxel in adult subjects with previously treated nonsmall cell lung cancer
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.